U.S. Markets closed

Why Ganaxalone Is a Promising Drug Candidate

Kenneth Smith

Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017....